Arrowhead Pharmaceuticals, Inc.
ARWR
Peringkat dalam Saham
#2370
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena,... Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
Harga Saham
$59.66
Kapitalisasi Pasar
$8.43B
Perubahan (1 hari)
1.26%
Perubahan (1 tahun)
56.88%
Negara
US
Perdagangan Arrowhead Pharmaceuticals, Inc. (ARWR)
Kategori
Healthcare
Pendapatan untuk Arrowhead Pharmaceuticals, Inc. (ARWR)
Pendapatan pada Jun 2026 TTM: $669.50M
Menurut laporan keuangan terbaru dari Arrowhead Pharmaceuticals, Inc., pendapatan saat ini (TTM) adalah $669.50M. Pada tahun 2024, perusahaan menghasilkan pendapatan sebesar $3.55M penurunan dibandingkan dengan pendapatan pada tahun 2023 yang sebesar $240.74M. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Arrowhead Pharmaceuticals, Inc. dari 2000 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Mengubah |
|---|---|---|
| 2026 (TTM) | $669.50M | -19.28% |
| 2025 | $829.45M | 23,258.15% |
| 2024 | $3.55M | -98.52% |
| 2023 | $240.74M | -1.03% |
| 2022 | $243.23M | 75.89% |
| 2021 | $138.29M | 57.16% |
| 2020 | $87.99M | -47.87% |
| 2019 | $168.80M | 945.67% |
| 2018 | $16.14M | -48.60% |
| 2017 | $31.41M | 19,736.49% |
| 2016 | $158.33K | -58.55% |
| 2015 | $382.00K | 118.29% |
| 2014 | $175.00K | -39.71% |
| 2013 | $290.27K | 97.63% |
| 2012 | $146.88K | -50.40% |
| 2011 | $296.14K | -52.24% |
| 2010 | $620.10K | -83.50% |
| 2009 | $3.76M | 188.38% |
| 2008 | $1.30M | 7.88% |
| 2007 | $1.21M | 102.87% |
| 2006 | $595.46K | 0.81% |
| 2005 | $590.68K | 200.90% |
| 2004 | $196.31K | 0.00% |
| 2003 | 0.00 | -100.00% |
| 2002 | $2.27K | -75.67% |
| 2001 | $9.31K | -62.57% |
| 2000 | $24.88K | 0.00% |
Pendapatan untuk perusahaan serupa atau pesaing
| Perusahaan | Pendapatan | Perbedaan Pendapatan | Negara |
|---|---|---|---|
| $12.62B | 1,785.65% |
US
|
|
| $2.23B | 232.79% |
US
|
|
| $15.74B | 2,251.67% |
AU
|
|
| $6.02B | 799.38% |
NL
|
|
| - | - |
CH
|
